Navigation Links
Sosei Confirms the Safety of SD118 in Two Phase I Trials
Date:12/8/2008

i Tamura, President & CEO of Sosei, said: "I am delighted that SD118 demonstrated a good safety profile, especially considering the wide range of doses tested. This project is now ready to move into the next step of development."

Notes for Editors:

About Neuropathic Pain

Neuropathic pain is caused by a primary lesion or dysfunction in the nervous system and persists for months or years even after the initial damage had been healed. It can occur in a variety of traumatic diseases including spinal cord injury and nerve compression. Also, it is a common secondary symptom in diseases like diabetes, cancer and herpes zoster infection, and can occur after the use of cytotoxic drugs. The condition has a poor prognosis and is a significant cause of morbidity. The neuropathic pain market is forecast to reach US$5.5 billion by 2010. Although there is no single definition of neuropathic pain, approximately 26 million patients worldwide suffer from some forms of the condition (Espicom, 2005). The management of neuropathic pain is still a major challenge to the pharmacotherapy due to its unresponsiveness to most of the pain-killers, anticonvulsants, antidepressants and in some cases, opioids.

    Paraesthesia
    A transient sensation of numbness or tingling ["pins and needles"].

    Hypoaesthesia
    A reduced sense of touch.

About Sosei

Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model based primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.so
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
2. Sosei Announces Completion of Phase III Trial for NorLevo(R)
3. National Study Presented at ACG 2008 Confirms New Device Functions Like Rear-View Mirror to Provide Improved View of the Colon
4. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
5. Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
6. New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
7. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
8. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
9. Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
10. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
11. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ANDOVER, Massachusetts y LONDRES, August 29, 2015 ... Inteligencia Anatómica para los sistemas ... reproducibles en Ecografía, tiempos de examen rápidos ... se traduce en mayor confianza diagnóstica en el proceso ... Philips  (NYSE: PHG, AEX: PHIA) ha anunciado hoy el ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Pranoprofen Market, ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma Corporation ... an inflammatory drug, pranoprofen was later developed into ... the trade name of pranopulin for the treatment ...
(Date:8/28/2015)... , Aug. 28, 2015 Patterson ... Inc. (Nasdaq: PDCO ), is now an ... announced acquisition of Patterson Medical by Madison Dearborn ... retain its name for a transition period before ... rehabilitation and sports medicine products.  With the focused ...
Breaking Medicine Technology:Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5Investigation Report on China's Pranoprofen Market, 2010-2019 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... April 3, 2011 Regado Biosciences, Inc., a privately ... active control agents, announced today the primary results of ... lead product, the anticoagulation system REG1, at the i2 ... Annual Scientific Session & Expo in New Orleans, LA. ...
... of the SPIRIT II, III, IV and COMPARE trials presented ... ABT ) market-leading XIENCE V ® Everolimus ... all four trials, two-year results on the safety and efficacy ... and TAXUS ® Express2™ Paclitaxel-Eluting Coronary Stent Systems ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 2Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 3Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 4Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 5Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® 2Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® 3Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® 4
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( http://www.nutricompany.com ... of global cosmeceutical and skin care brands. Mr. Fernandez comes with a ... years working in operations, purchasing and management for some of the nations biggest ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at ... Community Colleges , will be hosting a Job Expo to provide a professional, open ... The Expo has expanded to much more than just a typical job and career ...
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... ... due to insufficient scrotal support and protection against dribbled urine and sweat. "In ... from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides ...
(Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... Next ... end of summer (which astronomically, officially ends on September 22nd this year). For IT ... cyber security hangovers linger on which could prove far more costly than a simple ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... The popular ... James Earl Jones, recently announced that it will be devoting an entire short segment ... affecting millions of people around the globe on a daily basis, but recent advancements ...
Breaking Medicine News(10 mins):Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... Ill., Jan. 30 SpineMark Corporation,a spinal care ... develop Spine Centers of Excellence, has entered into ... spinal care at,cost effective rates through the first ... the Healthplace Surgery Benefit(TM). As a result,of ...
... Snyder, president of Catholic Charities USA, issued the ... the State Children,s Health Insurance Program (SCHIP), a ... that do not qualify for Medicaid. The House ... on a compromise version of the legislation, which ...
... Jan. 30 Wellesse, manufacturers of new Liquid ... challenges participants to assess their vitamin knowledge for ... a personal nutrition consultation and a year,s supply ... research on Vitamin D dominates the headlines lately, ...
... for menopausal symptoms, FDA says , , FRIDAY, Jan. ... hormones or "bio-identical hormone replacement therapy," and they ... lose weight to preventing senility. , They,re touted ... conventional hormone-replacement therapy. , But the U.S. Food ...
... Co., Inc. (NYSE Alternext: TPI), a manufacturer and ... Chengdu, China,today announced that the Company has begun ... stock repurchase program. These shares will be,retired to ... shares of its,common stock. , ...
... exclusivity on the 500 mg strengthPITTSBURGH, Jan. 30 ... that its subsidiary Mylan Pharmaceuticals Inc. has received final ... for its Abbreviated New Drug Application (ANDA) for Divalproex ... mg. Mylan has been awarded 180 days of marketing ...
Cached Medicine News:Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 2Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 3Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 4Health News:Catholic Charities USA Praises Congress for Protecting Health Care for Low-income Children 2Health News:Test Your Vitamin D Knowledge: Wellesse Liquid Sunshine Instant Win and Sweepstakes 2Health News:The Truth About 'Bio-identical' Hormone Therapy 2Health News:The Truth About 'Bio-identical' Hormone Therapy 3Health News:The Truth About 'Bio-identical' Hormone Therapy 4Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 2Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: